Sibley Memorial Hospital

Summary

Sibley Memorial Hospital is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Prostate Cancer, Lung Cancer, Breast cancer, Pancreatic Cancer and other specialties. Sibley Memorial Hospital is involved with conducting 217 clinical trials across 340 conditions. There are 32 research doctors associated with this hospital, such as Nilofer S. Azad, Michael J. Pishvaian, Channing Paller, MD, and Cesar A. Santa-Maria.

Top PIs

Clinical Trials running at Sibley Memorial Hospital

Breast Cancer

Bladder Cancer

Pancreatic Cancer

Prostate Cancer

Skin Cancer

Pancreatic Carcinoma

Colorectal Cancer

Cancer

Lung Cancer

Uterine Cancer

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria